Department of Children and Adolescents Oncology, Gustave Roussy, Paris-Saclay University, Villejuif, France.
Radiation Epidemiology Group, INSERM Unit 1018, Villejuif, France.
Neuro Oncol. 2024 Jul 5;26(7):1310-1324. doi: 10.1093/neuonc/noae045.
Optic pathway gliomas (OPGs) represent 5% of childhood brain tumors. Successive relapses lead to multiple treatments exposing to late complications.
We included patients treated at Gustave Roussy (GR) between January 1980 and December 2015 for OPG, before 18 years old and alive at 5 years from diagnosis. Mortality and physical health conditions data were extracted from medical data files and updated, thanks to the GR long-term follow-up program and French national mortality registry for patients included in the French Childhood Cancer Survivor Study.
We included 182 5-year OPG-childhood survivors in the analysis (sex ratio M/F 0.8, 35% with neurofibromatosis type 1 [NF1]). With a median follow-up of 17.2 years (range = 5-41), we registered 82 relapses, 9 second malignancies, and 15 deaths as first events after 5 years, resulting in 20-year conditional overall survival (C-OS) and late events-free survival of 79.9% (95% confidence interval [CI] = 71-86) and 43.5% (95% CI = 36-51), respectively. Radiotherapy exposure in NF1 patients (hazard ratio [HR] = 6, 95% CI = 1.7-21.2) and hypothalamic involvement (HR = 3.2, 95% CI = 1.4-7.3) were significantly associated with C-OS in multivariable analyses. Ninety-five percent of 5-year OPG survivors suffered from any health condition, especially visual acuity "<1/10" (n = 109), pituitary deficiency (n = 106), and neurocognitive impairment (n = 89). NF1 (HR 2.1) was associated with precocious puberty. With a median time post-diagnosis of 4.2 years, 33 cerebrovascular events were observed in 21 patients.
Late relapses, second malignancies, and cerebrovascular diseases are severe late events resulting in premature mortality. Morbidity is high and needs after-cancer care to improve quality of life. Risk factors could be considered to better stratify long-term follow-up.
视神经胶质瘤(OPG)占儿童脑肿瘤的 5%。连续复发导致多次治疗,引发晚期并发症。
我们纳入了 1980 年 1 月至 2015 年 12 月期间在 Gustave Roussy(GR)接受治疗的 OPG 患者,这些患者在 18 岁之前被诊断,并在诊断后 5 年时存活。通过 GR 长期随访计划和法国全国死亡率登记处,对患者的死亡率和身体健康状况数据进行了提取和更新,这些患者被纳入法国儿童癌症幸存者研究。
我们纳入了 182 名 5 年 OPG 儿童幸存者进行分析(男女性别比为 0.8,35%伴有神经纤维瘤病 1 型 [NF1])。中位随访时间为 17.2 年(范围 5-41 年),我们记录了 82 例复发、9 例第二恶性肿瘤和 15 例 5 年后首次发生的死亡事件,导致 20 年条件总生存(C-OS)和晚期无事件生存分别为 79.9%(95%CI 71-86)和 43.5%(95%CI 36-51)。NF1 患者的放疗暴露(风险比[HR] = 6,95%CI = 1.7-21.2)和下丘脑受累(HR = 3.2,95%CI = 1.4-7.3)在多变量分析中与 C-OS 显著相关。95%的 5 年 OPG 幸存者患有任何健康状况,特别是视力"<1/10"(n=109)、垂体功能减退(n=106)和神经认知障碍(n=89)。NF1(HR 2.1)与性早熟有关。中位诊断后时间为 4.2 年,21 名患者中有 33 例发生脑血管事件。
晚期复发、第二恶性肿瘤和脑血管疾病是导致过早死亡的严重晚期事件。发病率高,需要癌症后护理以提高生活质量。可以考虑风险因素来更好地分层长期随访。